A potential role for B-cell activating factor in the pathogenesis of autoimmune myasthenia gravis

Samia Ragheb, Robert Lisak, Richard Lewis, Gregory Van Stavern, Felicitas Gonzales, Kirk Simon

Research output: Contribution to journalArticlepeer-review

57 Scopus citations

Abstract

Objective: To compare serum B-cell activating factor (BAFF) levels in patients with myasthenia gravis (MG) with those in control subjects without MG. Design: Case-control study. Subjects: Forty-three patients with MG were compared with control subjects without MG. These included 48 healthy subjects, 25 patients with multiple sclerosis, and 3 patients with amyotrophic lateral sclerosis. Results: In all subjects studied, there was no correlation between the serum BAFF level and the concentration of total IgG, IgA, or IgM. The BAFF levels in patients with multiple sclerosis or amyotrophic lateral sclerosis were not significantly different from those in healthy subjects. However, BAFF levels in patients with MG were significantly higher than those of all the control subjects. There was no correlation or dependence between the serum BAFF level and the extent or severity of disease. There was a trend for BAFF levels to be higher in patients who were seropositive for acetylcholine receptor-specific antibodies. Conclusions: We report that BAFF levels are increased in patients with autoimmune MG. Our data suggest that BAFF is likely to play a role in the pathogenesis of MG by promoting the survival and maturation of autoreactive B cells.

Original languageEnglish
Pages (from-to)1358-1362
Number of pages5
JournalArchives of neurology
Volume65
Issue number10
DOIs
StatePublished - Oct 2008

Fingerprint

Dive into the research topics of 'A potential role for B-cell activating factor in the pathogenesis of autoimmune myasthenia gravis'. Together they form a unique fingerprint.

Cite this